Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer

Vaccine

Volumn 30, Issue 29, 2012, Pages 4394-4397

  Sims, Robert B ^a  

^a Dendreon   (United States)

Author keywords

Immunotherapy; Metastatic castrate resistant prostate cancer; Sipuleucel T

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AUTOANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MACROPHAGE ACTIVATING FACTOR; RECOMBINANT PROTEIN; SIPULEUCEL T; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHILL; DISEASE COURSE; FEVER; HEADACHE; HUMAN; HUMORAL IMMUNITY; HYPERHIDROSIS; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA; LEUKAPHERESIS; METASTASIS; MYALGIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MALE; NEOPLASM METASTASIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; TISSUE EXTRACTS;

EID: 84861988397     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.058     Document Type: Review

References (22)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011 June.
2. Graddis T.J., McMahan C.J., Tamman J., Page K.J., Trager J.B. Prostatic acid phasphatase expression in human tissues. Int J Clin Exp Pathol 2011, 4(3):295-306.
3. Laus R., Yang D.M., Ruegg C.L., Shapero M.H., Slagle P.H., Small E.J., et al. Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience. Cancer Res Ther Control 2001, 11:1-10.
4. Burch P.A., Breen J.K., Buckner J.C., Gastineau D.A., Kaur J.A., Laus R.L., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000, 6(June (6)):2175-2182.
5. Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18(December (23)):3894-3903.
6. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(August (16)):3670-3679.
7. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
8. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24(July (19)):3089-3094.
9. Flanigan R., Price T., Whitmore J., Holman J. Safety of leukapheresis in prostate cancer patients receiving sipuleucel-T. J Urol 2011, 185(4 (Suppl. 1)):e261. [abstract 646].
10. Hiagno C.S., Small E.J., Schellhammer P.F., Kantoff P.W., Redfern C.H., Nemunaitis J.J., et al. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28(15s). [abstract 4550].
11. Hall S.J., Klotz L., Pantuck A.J., George D.J., Whitmore J.B., Frohlich M.W., et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 2011, 186(3):877-881.
12. Sheikh N.A., Jones L.A. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008, 57(September (9)):1381-1390.
13. Sheikh N.A., Dela Rosa C., Kuan L.-Y., Stewart F.P., Frohlich M.W., Urdal D.L., et al. Sipuleucel-T generates robust and persistent cellular and humoral immune responses - results from the IMPACT trial [abstract] 2010, AACR, Washington, DC, [abstract 2932].
14. Stewart F.P., Dela Rosa C., Sheikh N.A., McNeel D.G., Frohlich M.W., Urdal D.L., et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. J Clin Oncol 2010, 28(15s). [abstract 4552].
15. Sheikh N.A., Dela Rosa C., Frohlich M.W., Urdal D.L., Provost N.M. Sipuleucel-T treatment results in sequential ex vivo activation of APCs and T cells during the culture step - evidence for in vivo immunological priming [abstract] 2010, AACR, Washington, DC, [abstract 5608].
16. Wesley J.D., Chadwick E., Kuan L-Y., Dela Rosa C., Frohlich M., Urdal D., et al. Characterization of antigen specific T cell activation and cytokine expression induced by sipuleucel-T. J Immunother 2010, 33(8):912-913.
17. Butterfield L.H., Disis M.L., Khleif S.N., Balwit J.M., Marincola F.M. Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Trans Med 2010, 8:130.
18. Sheikh N.A., Wesley J.D., Chadwick E., Perdue N., Dela Rosa C., Frohlich M.W., et al. Characterization of antigen specifric T-cell activation and cytokine expression induced by sipuleucel-T. J Clin Oncol 2011, 29(Suppl. 7). [abstract 155].
19. Gulley J.L., Drake C.G. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011, 17(June (12)):3884-3891.
20. Kudo-Saito C., Schlom J., Hodge J.W. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005, 11(6):2416-2426.
21. Madan R.A., Gulley J.L., Fojo T., Dahut W.L. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010, 15(9):969-975.
22. Tuma R.S. Immunotherapies in clinical trials: do they demand different evaluation tools?. J Natl Cancer Inst 2011, 103(10):780-781.